1821402-21-4
Chemical Structure
Efgartigimod alfa
Synonym(s): ARGX-113
- CAS No.: 1821402-21-4
- Formula:N/A
- Molecular Weight:(51.28 kDa)
IUPAC Name: 1,2,3,4-tetrakis(methyl-d3)benzene-5,6-d2
SMILES: [Efgartigimod alfa]
Biological Activity: Efgartigimod alfa (ARGX-113) is a reversibility, humanized Fc receptor antagonist . Efgartigimod alfa is a anti FcRn monoclonal immunoglobulin G (IgG1) Fc fragment. Efgartigimod reduces serum levels of total IgG, including pathogenic autoantibodies, by blocking FcRn function without permanent impairment. Efgartigimod alfa can be used for generalised myasthenia gravis (gMG) and primary immune thrombocytopenia research[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Efgartigimod alfa | 98.48% | Efgartigimod alfa (ARGX-113) is a reversibility, humanized Fc receptor antagonist . Efgartigimod alfa is a anti FcRn monoclonal immunoglobulin G (IgG1) Fc fragment. Efgartigimod reduces serum levels of total IgG, including pathogenic autoantibodies, by blocking FcRn function without permanent impairment. Efgartigimod alfa can be used for generalised myasthenia gravis (gMG) and primary immune thrombocytopenia research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Heo YA. Efgartigimod: First Approval. Drugs. 2022 Feb;82(3):341-348. [Content Brief]
- [2]. Heo YA. Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use. CNS Drugs. 2023 May;37(5):467-473. [Content Brief]
- [3]. Mansour GK, et al. Efgartigimod for Generalized Myasthenia Gravis and Beyond: A Narrative Review of Its Pharmacological Profile, Clinical Utility, and Expanding Applications. Biomedicines. 2025 Dec 4;13(12):2975. [Content Brief]
Keywords
